Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats

被引:0
|
作者
Machavaram, KK [1 ]
Gundu, J [1 ]
Yamsani, MR [1 ]
机构
[1] Kakatiya Univ, Univ Coll Pharmaceut Sci, Warangal, Andhra Pradesh, India
来源
PHARMAZIE | 2004年 / 59卷 / 12期
关键词
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The main aim of this study was to investigate the effect of various selective cytochrome P4503A (CYP3A) and/or P-glycoprotein (P-gp) modulators on biliary clearance of bromosulphaphthalein (BSP) in male albino wistar rats. Male albino wistar rats were divided into different groups, treated with CYP3A and P-gp modulators and BSP was administered intravenously (bolus or infusion) to each treated group. BSP in serum and bile samples was analyzed using spectrophotometric analysis at 580 nm. There was a statistically significant (p < 0.05) increase in serum BSP levels with CYP3A and P-gp substrates and/or inhibitors, cyclosporine-A, nitrendipine,quinidine, indinavir, claxorubicin, etoposide and erythromycin by 27%, 35%, 32%, 12%, 5%, 22%, and 106%, respectively. There was a slight increase (4%, p > 0.05) observed in serum BSP levels in the presence of ketoconazole, whereas CYP3A and P-gp inducers, rifampicin and sodium butyrate significantly (p < 0,05) decreased the serum BSP levels by 30% and 14% respectively, when compared to control group after 62 min of BSP i.v. bolus administration. In BSP infusion studies, Cyclosporine A, nitrendipine, quinidine, indinavir, ketoconazole, doxorubicin, etoposide, and erythromycin significantly decreased the bile BSP levels by 23%, 22%, 17%, 59%, 3%, 15%, 10%, 29%, respectively. Upon 60 min of BSP infusion, rifampicin and sodium butyrate significantly (p < 0.05) increased bile BSP levels by 33% and 25%, respectively. Finally, we observed that the P-gp and CYP3A inducers significantly decreased the total serum BSP levels and increased the total biliary levels of BSP, this could be by inducing P-gp in biliary canalicular membrane in male wistar rats. P-gp and CYP3A inhibitors and substrates significantly increased the total serum BSP levels and reduced the biliary excretion of BSP by inhibiting P-gp in biliary pathway. There was no significant difference observed between inhibitors and substrates of P-gp on BSP disposition. We suggest that the biliary transport of BSP could be useful as a simple and economical in vivo screening model for identifying P-gp and CYP3A substrates and/or inhibitors and/or inducers in wistar rats.
引用
收藏
页码:957 / 960
页数:4
相关论文
共 50 条
  • [21] The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity
    Kurnik, Daniel
    Wood, Alastair J. J.
    Wilkinson, Grant R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (03) : 228 - 234
  • [22] Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir
    Wang, Zhiying
    Pal, Dhananjay
    Mitra, Ashim K.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (09) : 3199 - 3213
  • [23] Potential risk of mulberry-drug interaction: Modulation on P-glycoprotein and cytochrome P450 3A
    School of Pharmacy, China Medical University, Taichung 404, Taiwan
    不详
    不详
    Juang, S.-H. (paul@mail.cmu.edu.tw), 1600, American Chemical Society (61):
  • [24] Possible roles of intestinal P-glycoprotein and cytochrome P450 3A on the limited oral absorption of irinotecan
    Yamasaki, Keishi
    Hidaka, Muneaki
    Kawano, Yohei
    Furuya, Yumiko
    Ono, Hiroshige
    Arimori, Kazuhiko
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2021, 73 (02) : 178 - 184
  • [25] Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib
    Yamamiya, Ikuo
    Hunt, Allen
    Takenaka, Toru
    Sonnichsen, Daryl
    Mina, Mark
    He, Yaohua
    Benhadji, Karim A.
    Gao, Ling
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (10): : 966 - 978
  • [26] Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor
    Zhang, YC
    Guo, XH
    Lin, ET
    Benet, LZ
    DRUG METABOLISM AND DISPOSITION, 1998, 26 (04) : 360 - 366
  • [27] Potential Risk of Mulberry-Drug Interaction: Modulation on P-Glycoprotein and Cytochrome P450 3A
    Hsu, Pei-Wen
    Shia, Chi-Sheng
    Lin, Shiuan-Pey
    Chao, Pei-Dawn Lee
    Juang, Shin-Hun
    Hou, Yu-Chi
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2013, 61 (18) : 4464 - 4469
  • [28] The effects of pregnancy on cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp) activity.
    Hebert, MF
    Unadkat, JD
    Carr, DB
    Kirby, B
    Eckert, L
    Easterling, TR
    JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2006, 13 (02) : 227A - 227A
  • [29] Pharmacokinetic Interactions of Herbs with Cytochrome P450 and P-Glycoprotein
    Cho, Hyun-Jong
    Yoon, In-Soo
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 2015
  • [30] The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates
    Lemma, GL
    Wang, ZQ
    Hamman, MA
    Zaheer, NA
    Gorski, JC
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (03) : 218 - 230